Skip to content

Study on the correlation between circulating endothelial cells and pulmonary hypertension

Study on the correlation between circulating endothelial cells and pulmonary hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-15006738
Enrollment
Unknown
Registered
2015-07-11
Start date
2016-06-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary hypertension

Interventions

test group:CECs test
Control group:CECs test

Sponsors

Wuhan Asia Heart Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 80 Years

Inclusion criteria

Inclusion criteria: The patients with pulmonary hypertension were divided into 3 groups according to different conditions: 1. stable and satisfactory group: n = 20 (no clinical manifestations of right ventricular failure, non syncope and heart function was stable in grade I to II, 6MWT>500m, BNP2.5L/ (min*?)); 2. stable but not satisfied group: n=20 (stable condition, but did not reach the state of the patient and physician satisfaction, and some indicators did not meet the above stability and satisfactory standards); 3. instability and deterioration group:n = 20 (right ventricular failure, deterioration o WHO cardiac function. 6MWT180pg/ml or NT-proBNP>1500pg/ml, pericardial effusion, right atrial pressure >15mmHg, CI<2.0L/ (min*m^2, edema aggravated, an increase in the number of syncope, frequent hemoptysis and ventricular arrhythmia).

Exclusion criteria

Exclusion criteria: Combining basic diseases which influenced the count of CECs, such as hypertension, atherosclerosis, tumor, thrombosis, renal disease, and so on.

Design outcomes

Primary

MeasureTime frame
CECs count;

Countries

China

Contacts

Public ContactZhang Gangcheng
yxsxs2015@163.com+86 18963980946

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026